Evidence map›Paper›PMID 40662268›Full record

ReviewCurrent opinion in hematology2025

Immune response to platelet transfusions.

Rachael P Jackman, Kimberly A Thomas

Abstract readReview
In one paragraph

Review in Current opinion in hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rachael P JackmanVitalant Research Institute.
Kimberly A ThomasVitalant Research Institute, Denver.

Funding

The impact of illness and medical treatments on the alloantibody response to platelet transfusionR01HL144501 · NHLBI · VITALANT · PI JACKMAN, RACHAEL PERETZ · 2019 to 2022
$3.0M
NHLBI NIH HHS R01 HL144501
6 · The paper itself

Abstract

purpose of reviewPlatelet transfusion can have a significant immunological impact, exposing the recipient to alloantigens on the surface of platelets and contaminating leukocytes, a dynamic range of soluble immune mediators, and donor platelets that can directly and indirectly contribute to the inflammatory profile of the recipient. Here, we will review recent developments in our understanding of the mechanisms regulating the immune response to platelet transfusion. RECENT

findingsUsing animal models, much has been learned about the mechanisms regulating the alloimmune response to platelet transfusion and how this response is shaped by the underlying health of the recipient. There is also a growing appreciation of the active role platelets play in immunity and their impact on the recipient immune system and transfusion outcomes, and how these immunological profiles are shaped by product collection, processing, and storage practices. SUMMARY: While platelet transfusion carries significant benefit to a wide range of patients, it carries risk of alloimmunization and other immune-mediated adverse reactions. Further characterization of the mechanisms regulating these outcomes can lead to new interventions to prevent alloimmunization and help to identify which platelet products are best suited to different patient populations.

Indexed as

Blood PlateletsPlatelet TransfusionAnimalsHumansalloimmunizationimmunomodulationinflammationplatelet transfusion

Identifiers

PMID40662268
PMCPMC12266639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.